Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors

被引:0
作者
Joerg Schrader
Frank O. Henes
Michael Blaeker
Katharina Zimmermann-Fraedrich
Andrea Pace
Daniel Perez
Jakob R. Izbicki
Ansgar W. Lohse
Daniel Benten
机构
[1] University Medical Center Hamburg-Eppendorf,Department of Medicine – Gastroenterology and Hepatology
[2] University Medical Center Hamburg-Eppendorf,Department of General, Visceral and Thoracic Surgery
[3] University Medical Center Hamburg-Eppendorf,Department for Diagnostic and Interventional Radiology
来源
Endocrine | 2019年 / 65卷
关键词
Neuroendocrine tumor; Chemotherapy; Streptozotocin; 5-FU;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:460 / 467
页数:7
相关论文
共 185 条
[1]  
Moertel CG(1992)Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N. Engl. J. Med. 326 519-523
[2]  
Lefkopoulo M(2016)Vienna Consensus Conference, p.: ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site Neuroendocrinology 103 172-185
[3]  
Lipsitz S(2005)Eastern Cooperative Oncology, G.: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281 J. Clin. Oncol. 23 4897-4904
[4]  
Hahn RG(1984)Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J. Clin. Oncol. 2 1255-1259
[5]  
Klaassen D(2015)Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms–Predictive and Prognostic Markers for Treatment Stratification PLoS ONE 10 1253-1262
[6]  
Pavel M(2015)Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours Eur. J. Cancer 51 345-353
[7]  
O’Toole D(2016)Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity Neuroendocrinology 103 228-247
[8]  
Costa F(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 45 805-835
[9]  
Capdevila J(2007)Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration Epidemiology 18 514-523
[10]  
Gross D(2011)Rad001 in Advanced Neuroendocrine Tumors, T.T.S.G.: Everolimus for advanced pancreatic neuroendocrine tumors N. Engl. J. Med. 364 501-513